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Abstract: Ternary Ni(II) complexes of hydrazine and eight heterocyclic sulfonamides possessing carbonic
anhydrase (CA) inhibitory properties, were prepared and characterized by elemental analysis, spectroscopic,
magnetic, thermogravimetric, and conductimetric measurements. The complexes behave as strong inhibitors
for two isozymes (I and II) of carbonic anhydrase.
Introduction
Heterocyclic sulfonamides constitute a class of strong inhibitors of the zinc enzyme carbonic
anhydrase (CA, EC 4.2.1.1), and have wide clinical applications in the treatment of a variety of disorders such
as glaucoma, gastro-duodenal ulcers, and acid-base disequilibria among others. Compounds 1-6 are all
clinically used such drugs, with acetazolamide 1, methazolamide 2 and ethoxzolamide 3 being first
generation inhibitors (without specificity for different CA isozymes or selectivity for diverse organs where
these enzymes are present), benzolamide 5 and chlorzolamide 6 having the status of orphan or experimental
drugs
4 (and also showing specificity for some CA isozymes in certain concentrations3’4, whereas sezolamide
4 is the representative of a novel class of such inhibitors (third eneration) recently introduced in clinical
medicine as topically effective drugs in the treatment of glaucoma. 5-Amino-1,3,4-thiadiazole-2-sulfonamide
7 is on the other hand the key compound for synthesis of diverse inhibitors such as 1, 2, 5 or 8. This last
compound is a member of a novel class of recently developed membrane-impermeant derivatives which
selectively inhibit membrane-bound isozyme CA IV.
Recently, our 7roups proved that metal complexes of heterocyclic sulfonamides behave as even
stronger CA inhibitors, and their mechanism of action was also explained, as being due to a dual inhibition
by sulfonamido anions and metal ions, formed by dissociation of the complex inhibitor, which subsequently
9 10II bnd to dfferent stes of the enzyme. Metal ons probably bnd to catalytically critical hstdne residues
whereas the sulfonamido anions coordinate to the Zn(II) ion within CA active site.
12
A large series of such complexes was reported in the last years, containing mainly acetazolamide 1,
methazolamide 2 and ethoxzolamide 3 as ligands, and structures were determined for some of them by means
81314 of X-ray crystallography and spectroscopic methods," although some other ligands were investigated
too.
’7’4 As the coordination chemistry of this type of ligands is sometimes complicated due to their
versatility and large number of donor atoms present in their molecules, it is of great interest to investigate
some other ligands, as well as ternary complexes containing heterocyclic sulfonamides and amine-type
27 hgands, also due to their possible pharmacological apphcatons.
In this paper we report the preparation and characterization by spectroscopic, magnetic,
conductimetric and thermogravimetric methods of Ni(II) complexes of sulfonamides 1-8 and hydrazine as
ligands. The prepared complexes behave as very efficient inhibitors of human isozymes CA I and CA II.
# Presented in part at the European Research Conference "Chemistry of Metals in Biological Systems", San
Miniato, Italy, 1995.
*Correspondence author.
143Vol. 3, No. 3, 1996 Complexes with BiologicallyActive Ligands. Part 6.
CH3 SO2NH2
1: H2aaz
N
C2H O2NH2
3: Heza
IkHCH2CH(CH3)2
2
4: Hsza
SO2NH2
N N
C6H5s02NH#""S"S02NH2
5: H2bza
CI
SO2NH2
6: Hcza
7: Htda
H3 LIso2NH2
CH3
CIO4-
CH3
8: Hcts
Materials and Methods
IR spectra were recorded on a Perkin Elmer 881 instrument, in the range 200-4000 cm-1, in KBr
pellets. Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference, with a
Perkin Elmer Lambda 15 apparatus, in the range 200-900 cmI. Conductimetric measurements were done in
DMF solutions, at 25C (concentrations of mM of complex) with a Fisher conductimeter. Magnetic
susceptibility measurements were carried out at room temperature with a fully automized AZTEC DSM8
pendulum-type susceptometer. Mercury(II) tetrakis(thiocyanato)cobaltate(II) was used as a susceptibility
standard. Corrections for the diamagnetism were estimated from Pascal’s constants.
15 Elemental analyses were
done by combustion for C,H,N with an automated Carlo Erba analyzer, and gravimetrically for the metal
ions, and were + 0.4% of the theoretical values. Thermogravimetric measurements were done in air, at a
heating rate of 10C/min., with a Perkin Elmer 3600 thermobalance.
Acetazolamide, methazolamide and human CA I and CA II were from Sigma. Sulfonamides 3,4,6-8
used in the syntheses were prepared as described in the literature.
5’6 Metal salts, organic reagents used for
preparing the sulfonamides and solvents were from Aldrich and were used without additional purification.
Benzolamide 5 was a gift from Dr. T.H.Maren (University of Florida, Gainesville). Inhibitors were assayed
by Maren’s micromethod 7, in the conditions of the E-I (enzyme-inhibitor) technique, at 0C in veronal
buffer. ICs0 values represent the molarity of inhibitor producing a 50% decrease ofCA specific activity for the
CO2 hydration reaction.
Synthesis of coordination compounds 9-16
10 mMoles of sulfonamide 1-8 were dissolved in the minimum amount of ethanol (generally 50-200 mL).
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To this solution was added l0 mL of aqueous solution containing 5 mMoles Ni(II) salt (nitrate, or chloride)
and the obtained solution was treated with an excess (3 mL) of hydrazine hydrate 80%. The mixture was
stirred magnetically at room temperature for 2 hours, then the obtained precipitates were filtered and air-dried.
Yields were in the range of 56-95%.
Results and Discussion
The prepared complexes and their proposed formulas (based on elemental analysis, 0.5% of the
theoretical values) are shown in Table I.
Table I Prepared complexes 9-16, containing hydrazine and heterocyclic sulfonamides, and their elemental
analysis data..
No. Complex Color Yield Analysis (calculated/found)
(%) %M ocb %H %N
9 [Ni2(aaz)2(NzH4)2]
10 [Ni2(mza)2(N2H4)z(OH)2]
11 [Ni(eza)(N2H4)2(OH)]
12 [Ni(sza)(NzH4)]
13 [Ni(Hbza)(N2H4)4(OH)]
14 [Ni(cza)(NzH4)(OH)]
15 [Ni(tda)(N2H4)4(OH)]
16 [Ni(cts)z(NzH4)2](C104)2
violet 56 18.8/18.5 15.4/15.1 3.5/3.3 26.9/26.7
violet 45 16.9/17.1 17.5/17.4 3.5/3.3 24.5/24.5
lilac 67 14.8/14.6 27.2/27.0 4.5/4.4 21.1/20.8
lilac 42 14.1/14.1 28.8/28.5 5.0/5.2 13.4/13.0
violet 57 11.1/10.7 18.4/18.0 4.6/4.6 32.1/31.9
violet 75 15.1/15.2 25.1/25.1 2.6/2.6 18.3/18.1
lilac 34 15.1/14.7 6.2/6.2 5.2/5.3 43.9/44.1
violet 18 6.5/6.8 26.9/30.1 3.6/3.5 18.8/18.9
aBy gravimetry; bBy combustion.
The new compounds 9-16 were also characterized by means of spectroscopic (IR and electronic
spectra), thermogravimetric, conductimetric and magnetic measurements. Some of these data are shown in
Tables II and IV.
Table II: IR spectra, magnetic moments at room temperature, thermogravimetric and conductimetric data for
complexes 9-16.
Comp. IR. Spectra a, cm- kteff b, (BM)
m(so2)s A(SO2)
TG analysis Conductimetry
d
found/calc. AM (f-I x cm2x mo1-1)
9 5 14 2.34 10.2/10.1 12
1 0 10 12 2.56 9.2/9.3 10
1 1 10 15 2.89 16.0/16.1 9
1 2 7 18 3.43 7.7/7.5 17
1 3 21 20 2.40 24.7/24.5 8
1 4 9 17 2.91 8.3/8.3 12
1 5 8 14 3.68 33.3/33.5 15
1 6 12 19 4.10 7.2/7.0 285
In KBr pellets; A(SO2) (SO2)sulfonamid (SO2)complex At room temperature; Weight loss, % (only first
step), corresponding to: e2N2H4; flN2H4; g4N2H4 Solution mM (DMF) at 25C; 1:2 electrolyte.
In the IR spectra of the complex derivatives, the main change as compared to the uncomplexed
sulfonamides was the shift of the SO2 vibrations (in the range 1100-1180 cm for the antisymmetric
vibrations, and 1300 1376 cm-
for the symmetric vibrations, respectively, in derivatives 1-8)
2"5.7 to lower
wavenumbers (with 5 20 cm-), as for previously reported such complexes.
7.8.t3-5 The thiadiazole bands
around 1500 1600 cm-
are also slightly shifted to lower wavenumbers in the spectra of the complexes as
compared to the corresponding sulfonamide (data not shown), suggesting a possible interaction of Ni(II) with
some of the endocyclic nitrogens of compounds 1-8 too. Moreover, the hydrazine vibration,
TM around 970
-1 cm ,was also detected in the IR spectra of complexes 9-16.
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Table III: Electronic spectral data of complexes 9-16.
Complex Band (cm) Calculated Parameters
17,825 (v3) i0Dq 7,045 cm
11, 11 (v2) B 521.84 cm
7,045.5 (v) 13 0.54
10 18,587 (v3) 10Dq 7,150 cm
11,450 (V2) B 571.90 cm
7,150 (v) 0.53
27,050 (sh)
11 18,747 (v3) 10Dq 7,045 cm
11,507 (v2) B 581.80 cm
-t
7,170 (v) 0.54
28,329 (sh)
17,690 (v3) 10Dq 7,076 cm
1
11,111 (v2) B 505.43 cm
7,076 (v) I 0.47
14 18,818 (v3) 10Dq 7,341 cm
11,655 (v2) B 564.68 cm
7,342 (v) 13 0.52
24,570 (sh)
15 18,491 (v.0 10Dq 7,150 cm
11,450 (v) B 571.91 cm
t
7,150 (v) [ 0.53
28,329 (sh)
16 19,870 (v3) 10Dq 6,206 cm
11,480 (v2) B 1,034.41 cm
5,280 (v) 13 0.96
Band of thev transition was calculated
As seen from data of Tables II, the effective magnetic moments of complexes 11, 12, 14 and 15
suggest an octahedral environment of Ni(II), whereas for 16, a tetrahedral geometry of the metal ion is
assumed. The other three complexes (9, 10 and 13) have magnetic moments lower than the only spin
component (2.83 BM), suggesting that any magnetic coupling between the two Ni(II) ions appears for the
dinuclear derivatives, 9 and 10.19
Reflectance diffuse (RD) spectra of the newly synthesized complexes are shown in Table III, together
with some calculated parameters.
As seen from data of Table III, in the reflectance spectra of complexes 9-15, a band appears in the
visible range (around 18,000 cm-1) and another one in the near infrared region, around 11,000 cm-, suggesting
an octahedral environment of the Ni(II) ion(s).
19 The spectrum of compound 16 on the other hand shows a
broad band centered at approximately 19,870 cm
-1 and another one at 11,480 cm
-I which indicate a distorted
tetrahedral geometry of Ni(II) in this complex.
9 Table IV also shows the assignment of the bands using the
2o Lever tables. The results of RD spectra are thus in agreement with those of magnetic measurements,
suggesting octahedral Ni(II) ions in all but the last complex (16), which presumably contains tetrahedral
Ni(II).
The donor system of the conjugated base of sulfonamides 1-7 is probably constituted by the anionic
nitrogen of the sulfonamido moiety and the endocyclic nitrogens, excepting for sezolamide 4 where probably
the endocyclic sulfur participates in coordination. The positively-charged sulfonamide 8 on the other hand
seems to act as monodentate ligand when deprotonated at the sulfonamido moiety, by means of the
sulfonamido nitrogen. Hydrazine probably acts as both mono., bidentate and bridging bidentate ligand in the
prepared complexes. TG and conductimetric data (Table II) are in agreement with the above proposals. As no
appropriate crystals for X-ray diffraction experiments could be obtained, the precise structure of the prepared
complexes is not assigned for the moment.
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Biological activity data with the new complexes (compared to that of the sulfonamide from which
they derive) are presented in Tables IV and V.
Table IV: Biological activity data of sulfonamide CA inhibitors and complexes containing hydrazine and
metal ions (ICs0 represents the molarity of inhibitor producing a 50% decrease of enzyme specific activity for
17 the CO2 hydration reaction, by Maren’s micromethod ).
Compound ICs0 (nM)
CA I CA II
1 200 7
2 10 9
3 0.6
4 >5.106 2
5 2
6
7 280 30
8 165 14
9 105 5
10 1.8 4
1 1 0.4 0.2
12 800
13 0.9 O.8
14 0.7 0.5
15 150 2O
1 6 80 8
As seen from data of Table IV, the new complexes prepared by us behave as strong inhibitors for
both investigated CA isozymes, with potencies larger than those of the corresponding sulfonamides.
Generally, complexes were 1.1 5.5 times more active than the free sulfonamides from which they were
prepared. The notable exception is 12, which is more than 6000 times more inhibitory towards CA I, as
compared to sezolamide 4. No explanation for this large difference of activity is available for the moment,
but in Table V some comparative data are shown regarding CA I inhibition with sezolamide 4, Cu(II) ions as
well as complex 12. From such data, one can conclude that at least for isozyme CA I, the enzyme inhibition
observed with this class of derivatives is due to the metal complex per se, and not to its dissociation products
formed in dilute solution (metal ions and sulfonamido anions), as hypothesized eralier by us.
7’8
Table V: CA I inhibition data with sezolamide 4, Cu(II) ions (as copper(II) sulfate) and the complex 12.
System %CA I activity
CA I + 4 98
CA I + Cu2+’d 91
CA I +( 4 + Cu2+) 90
CA I + 12 50
aCA activity in the same conditions and in the absence of inhibitors is taken as 100%.
In all experiments [CA I] 10 nM, 50 mM veronal buffer (pH 7.9).
[4] 0.8
[Cu2+] 0.8 laM
[4] [Cu2+] 0.8M
[12] 0.8 M.
The increased activity as enzyme inhibitors of metal complexes of sulfonamides might be thus
accounted on their direct binding to the enzyme, in undissociated formed, in addition to the previous
explanation that the effect is due to a dual inhibition by metal ions and sulfonamido anions formed in dilute
solution by dissociation of the complex.
7’8
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